Shares of JIANGXI BIO (06915) plunged more than 14% at one point during Tuesday’s trading session, a notable reversal after the stock had hit an all-time high of HK$21.1 just a day earlier. At the time of writing, the stock was down 8.83% at HK$18.18, with turnover reaching HK$7.21 million.

On August 31, the company released its interim results for fiscal 2026, reporting revenue of RMB 83.3 million, a decline of approximately 16.5% year-on-year. Research and development expenses rose by 18.6% to RMB 11 million, while net profit fell sharply by 61% to RMB 14.366 million. Excluding one-time items such as listing expenses and tax rate adjustments, adjusted net profit stood at approximately RMB 38.7 million, down 21.7% from the prior year.

The earnings decline was primarily attributed to higher R&D spending, changes in national tax policies, reduced investment income, increased depreciation on fixed assets, and one-off listing costs. For its core product, human TAT (tetanus antitoxin), sales revenue during the period reached approximately RMB 77.5 million, with sales volume of about 9.577 million units—5.911 million domestically and 3.666 million overseas.

The group continues to advance its dual-packaging strategy for ampoules and vials, while expanding terminal market reach to strengthen operational resilience. Domestically, the company's products now cover 27,100 medical institutions. Notably, its vial products have been listed on medical procurement platforms across 32 provinces and municipalities, and have successfully secured supplementary provincial alliance centralized procurement contracts in 26 regions.